• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

BerGenBio

Selective AXL inhibitors

  • About BerGenBio
    • About BerGenBio
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline overview
    • bemcentinib | NSCLC
    • bemcentinib | COVID-19
    • bemcentinib | Melanoma
    • bemcentinib | AML
    • BGB149
    • BGB601
    • Discovery
    • Publications
    • Expanded access policy
  • Media Centre
    • News
    • Events
    • COVID-19 Media Pack
    • Media Contacts
  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts
  • Careers
  • Contact
Home  /  Events  /  BerGenBio to present updates from ongoing Phase II bemcentinib combination study in refractory NSCLC at WCLC 2020

BerGenBio to present updates from ongoing Phase II bemcentinib combination study in refractory NSCLC at WCLC 2020

Jan 29, 2021

Share This Post

Add to Calendar 01/29/2021 08:00 AM Europe/Oslo BerGenBio to present updates from ongoing Phase II bemcentinib combination study in refractory NSCLC at WCLC 2020 For more information visit: https://www.bergenbio.com/bergenbio-to-present-updates-from-ongoing-phase-ii-bemcentinib-combination-study-in-refractory-nsclc-at-wclc-2020/

Date: 29th January 2021

Time: 09.50 AM Singapore Time / 02.50 AM CET

Title: A phase II study of the oral selective AXL inhibitor bemcentinib with pembrolizumab in refractory patients with advanced NSCLC

Presenting Author: Dr. Matthew G. Krebs PhD.

Session/Abstract ID: Immunotherapy (Phase II/III Trials) # 3647

The presentation can be found at www.bergenbio.com under Investors / Presentations

Primary Sidebar

  • Media Centre
  • News
  • Events
  • COVID-19 Media Pack
  • Media Contacts

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.

Footer

Key Information

  • Pipeline
  • Investors
  • News
  • Presentations
  • Management Team

Useful Information

  • Privacy Policy
  • Terms of Use
  • Job Applicant Privacy Notice
  • Site Map

Get In Touch

BerGenBio ASA
Company registration number 992 219 688

Jonas Lies vei 91, 5009 Bergen, Norway

www.bergenbio.com

+ 47 559 61 159

Copyright © 2017 BerGenBio ASA. All right reserved. Designed by Utopian Designs